Skip to main content

MYRIAD GENETICS INC

For the period ended Dec 31, 2023. Filed Feb 28, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 28, 2024

MYGN$5.67-1.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on February 28, 2024.

MYRIAD GENETICS, INC.
By:/s/ Paul J. Diaz
Paul J. Diaz
President and Chief Executive Officer

Power of Attorney

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Paul J. Diaz and Scott J. Leffler and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated below and on the dates indicated.

SignaturesTitleDate
President, Chief Executive Officer and Director (Principal Executive Officer)
By:/s/ Paul J. DiazFebruary 28, 2024
Paul J. Diaz
Chief Financial Officer (Principal Financial Officer)
By:/s/ Scott J. LefflerFebruary 28, 2024
Scott J. Leffler
Chief Accounting Officer (Principal Accounting Officer)
By:/s/ Natalie MunkFebruary 28, 2024
Natalie Munk
By:/s/ S. Louise PhanstielChair of the BoardFebruary 28, 2024
S. Louise Phanstiel
By:/s/ Paul BisaroDirectorFebruary 28, 2024
Paul Bisaro
By:/s/ Heiner DreismannDirectorFebruary 28, 2024
Heiner Dreismann, Ph.D.
By:/s/ Rashmi KumarDirectorFebruary 28, 2024
Rashmi Kumar
By:/s/ Lee N. NewcomerDirectorFebruary 28, 2024
Lee N. Newcomer, M.D.
By:/s/ Colleen F. ReitanDirectorFebruary 28, 2024
Colleen F. Reitan
By:/s/ Daniel M. SkovronskyDirectorFebruary 28, 2024
Daniel M. Skovronsky, M.D., Ph.D.
By:/s/ Daniel K. SpiegelmanDirectorFebruary 28, 2024
Daniel K. Spiegelman
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.